SUPPLEMENTARY MATERIAL

Rifabutin acts in synergy and is bactericidal with frontline *Mycobacterium abscessus* antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination

Mark Pryjma, Jan Burian, and Charles J. Thompson*

Department of Microbiology and Immunology and the Centre for Tuberculosis Research, University of British Columbia, Vancouver, Canada, V6T 1Z3

*To whom correspondence should be addressed:

Tel: 1-604-822-2501

Email: charles.thompson@ubc.ca




Figure S1. Mycobacterium abscessus checkerboard plots of rifabutin in combination with various antibiotics. MAB ATCC19977 MICs to rifabutin were measured in the presence of sub-MIC concentrations of A) clarithromycin, B) azithromycin, C) roxithromycin or D) tigecycline. Alternatively, E) the tigecycline MIC was measured in the presence of sub-MIC concentrations of clarithromycin. Concave curves represent positive interactions between two antibiotics approaching synergy. FICI values for antibiotic combinations are shown. FICI ≤0.75 represents synergy.




Figure S2. Effect of rifabutin and azithromycin or roxithromycin combinations on *Mycobacterium abscessus* viability. *MAB* ATCC19977 cultures at OD600=0.005 were exposed to A) azithromycin at 1x (3.1 mg/L), 1/2x or 1/4xMIC, B&E) Rifabutin at 1x (6.3 mg/L), 1/2x or 1/4xMIC, C) a combination of azithromycin and rifabutin at 1x, 1/2x, and 1/4xMIC of each antibiotic, D) roxithromycin at 1x (3.1 mg/L), 1/2x or 1/4xMIC, or F) roxithromycin and rifabutin at 1x, 1/2x or 1/4xMIC of each antibiotic. CFUs were determined at 24 h intervals post antibiotic addition. The dashed line represents the limit of detection. Data points are the means of three replicates with standard deviation presented as error bars.




Figure S3. **Schematic representation of 3D checkerboard.** Arrows describe descending concentrations of the respective antibiotic along the axis indicated.




Figure S4. Isobologram showing interaction of clarithromycin, tigecycline and rifabutin against *Mycobacterium abscessus*. Concave areas represent synergistic drug interactions.